Navigation Links
Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
Date:6/11/2008

SEATTLE and PARIS, June 12 /PRNewswire-FirstCall/ -- Targeted Genetics Corporation (Nasdaq: TGEN) announced today that positive results of a Phase 1/2 clinical study demonstrate that tgAAC94, its investigational agent designed to inhibit activity of tumor necrosis factor-alpha (TNF-alpha), a key mediator of inflammation, is well tolerated and may improve disease symptoms in inflammatory arthritis patients refractory to other therapies, including systemic TNF antagonists. Full results of the study were presented here today during an oral presentation at the Annual European Congress of Rheumatology (EULAR).

The Phase 1/2 study evaluated multiple doses of tgAAC94 administered directly to affected joints with or without concurrent systemic TNF antagonist therapies. The study achieved its primary endpoint of safety and tolerability.

"We are encouraged by the patient-reported symptom improvement -- early signs of efficacy that indicate further study is warranted," said Philip Mease, M.D., Chief, Rheumatology Clinical Research Division of Swedish Hospital Medical Center and Head of Seattle Rheumatology Associates, who presented the data.

Study Details

127 patients with inflammatory arthritis received a single intra-articular injection of either tgAAC94 or placebo, followed by a second injection 12-30 weeks later depending on when the injected joint met criteria for re-injection. tgAAC94 was well tolerated at all dose levels. Two SAEs of focused interest were reported -- a culture-negative septic arthritis considered probably related to study drug and a fatal disseminated histoplasmosis and retroperitoneal hemorrhage considered not related to study agent. Administration site reactions were observed in 12% of subjects.
'/>"/>

SOURCE Targeted Genetics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Phase 1/2 Trial of Motexafin Gadolinium Plus Antibody Targeted Radiation Therapy Demonstrates High Complete Response Rate in Patients With Non-Hodgkins Lymphoma
2. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
3. Genomic Health Announces Results of Initial Studies to Develop Predictive Tests for Targeted Therapies
4. Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G - Demonstrates Dose-Dependent Anti-Tumor Activity Without Toxicity in Patients With Progressive Chemo-Resistant Bone and Soft Tissue Sarcoma (ASCO 2008)
5. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
6. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
7. Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)
8. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
9. Semafores PI3 Kinase Inhibitor SF1126 is a Vascular Targeted Conjugate in Phase I Clinical Trials in Solid Tumors and Multiple Myeloma
10. Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
11. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... 2015   Bernstein Liebhard LLP is ... the "Company") (NASDAQ: AERI ) issued materially ... of the federal securities laws; or (ii) the ... duties to shareholders. Aerie is a ... and commercialization of first-in-class therapies for the treatment ...
(Date:4/24/2015)... 24, 2015  A new study shows an "alarming rise" ... used to slow the progression of multiple sclerosis or reduce ... researchers at Oregon Health & Science University (OHSU) and Oregon ... number of MS drugs in the marketplace over the past ... costs for patients who use those drugs. Researchers found the ...
(Date:4/24/2015)... --  Vestagen Technical Textiles, Inc. today announced that ... received two notable innovation awards. The first is the ... with potential to create a positive impact in the ... New York City , VESTEX received the Silver ... category. The awards honor excellence in new product and ...
Breaking Medicine Technology:Bernstein Liebhard LLP Investigates Claims On Behalf Of Those Who Invested In Aerie Pharmaceuticals, Inc. 2Researchers find alarming rise in cost of MS drugs over past two decades 2Researchers find alarming rise in cost of MS drugs over past two decades 3Researchers find alarming rise in cost of MS drugs over past two decades 4VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 2VESTEX Wins Innovation Honors from Edison Awards & Apparel Magazine 3
... 2011 Abaxis, Inc. (NasdaqGS: ABAX), a medical products company ... to discuss its financial results for the second quarter of ... be at 4:15 p.m. ET on Tuesday, October 25, 2011. ... of fiscal year 2012 after the market closes on Tuesday, ...
... Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL ), a specialty ... on Monday, October 31, 2011 before the opening of the ... call that day at 10:00 a.m. ET to discuss results ... to be used during the call will be available on ...
Cached Medicine Technology:Abaxis to Report Second Quarter Fiscal Year 2012 Financial Results Tuesday, October 25, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 2Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011 3
(Date:4/25/2015)... April 26, 2015 The National ... , a national endeavor to prepare nurses to provide ... a great success, according to a new report by ... original funding partners. , The project began in ... (CCP), under the direction of Elaine Tagliareni, EdD, RN, ...
(Date:4/25/2015)... The Hon. Ellen Tauscher, Independent Chair of ... statement following the deadly earthquake in Nepal: , "Today ... the deaths of more than 1,000 people. The ... Bangladesh, India and other parts of South Asia. ... people of Nepal and the families of the victims. ...
(Date:4/25/2015)... 2015 By definition, a CIO’s responsibility is ... enterprise relying on their judgement and expertise to keep digital ... to an article published in National Mortgage News on ... doing a disservice to their responsibilities by focusing too heavily ... are crossed when it comes to company policy and industry ...
(Date:4/25/2015)... Parker and Sons projects growth in 2015. ... in Arizona alongside the growing economy. As a result, Parker ... April to help account for the rising need for heating, ... is something we are enthusiastic about. It means growth for ... at Parker and Sons. , Indeed, Parker and Sons has ...
(Date:4/25/2015)... For thirteen years, the Twin Cities DI ... event in the nation! This year, on May 5th, 2015, ... to take DI Day on the road by supporting the ... ChFC, RHU, DIA, CLTC, Chief Executive Officer at Secura Consultants ... the change by stating, "The first Twin Cities DI Day ...
Breaking Medicine News(10 mins):Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:Parker and Sons Plans to Expand in 2015 2Health News:Secura Consultants Takes DI Day On The Road 2
... NEW YORK, June 10 Tongji Healthcare, Inc.,(OTC Bulletin ... in China, reports that its hospital are enjoying an,influx ... province., Due to its status as a private ... Beijing that he has suggested the government would,pick up ...
... As nearly 80 percent of adults,experience back pain ... Carolina this month will launch a free, back care ... of the most common medical problems and affects eight,out ... In South Carolina, back,disorders were among the top causes ...
... of patients with testicular cancer are cured nowadays, but ... survivors, the medical profession and national governments, a cancer ... on Teenage and Young Adult Cancer Medicine, which is ... and 10). , Dr Craig Nichols, director of program ...
... The Endocrine Society will present Ronald S. ... Biomedical Research Institute at Harbor-UCLA Medical Center (LA ... annual convention June 15-18 in San Francisco. , ... members representing the full range of disciplines associated ...
... But their tech savvy helps them use online programs ... June 10 (HealthDay News) -- Insomnia among U.S. combat ... seen in patients with chronic insomnia, according to University ... post-deployment adjustment disorders to 14 insomnia patients and 14 ...
... Mylan Inc. (NYSE: MYL ),announced today ... agreement with,NATCO Pharma Ltd. (NATCO) for NATCO,s glatiramer ... which is used to treat,multiple sclerosis. The agreement ... and all major markets in Europe, Australia, New,Zealand, ...
Cached Medicine News:Health News:Tongji Healthcare Services Reports Influx of Patients 2Health News:BlueChoice HealthPlan to Launch Back Care Program 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 2Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 3Health News:Experts highlight gaps in knowledge on caring for survivors of teenage and young adult cancers 4Health News:LA BioMed investigator wins Distinguished Educator Award 2Health News:Combat Vets Display Severe Sleep Disorders 2Health News:Mylan Inc., NATCO Pharma Ltd. To Collaborate on Worldwide Marketing and Distribution of Generic Copaxone(R) 2
The Guidant Fineline EZ leads with protective capsule are bipolar endocardial and designed for permanent implantation with pulse generators for cardiac pacing....
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... The Model 6491 unipolar ... designed for temporary atrial and ... and after cardiac surgery. This ... downsized, making it the ideal ...
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
Medicine Products: